The total prevalent population of this debilitating, chronic condition will increase in all markets over the next 20 years.
Rheumatoid arthritis (RA) is a chronic, inflammatory, and systemic autoimmune disease that can lead to progressive joint deformity, disability, and sometimes premature death. The primary source of inflammation is in the synovium which leads to common symptoms including pain, stiffness, swelling and limited mobility and function in the affected joints. The etiology of RA remains to be elucidated, however, it is believed that onset in many RA patients is facilitated by an inflammatory process that occurs in genetically predisposed individuals, who are then exposed to environmental triggers.
Datamonitor Healthcare estimates that in 2015, there were 4.3 million total prevalent cases of RA in the US, Japan, and five major EU markets. By 2035, the number of total prevalent cases of RA is expected to increase across all of the analyzed markets to 5.2 million (a 22.2% absolute increase). All analyzed countries are expected to experience an increase, with the largest increase expected in the US. The forecasted increase in prevalent cases is due to evidence showing a consistent increase in prevalence proportions in analyzed countries. Prevalent cases in females predominated in all markets (69.9% of RA cases overall), ranging from 60.6% in Japan to 85.8% in France.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>